Quarterly ResultJun 15, 2026, 04:07 PM
Clearmind Medicine Reports Wider Net Loss; Assets and Equity Grow
AI Summary
Clearmind Medicine Inc. reported its unaudited condensed interim consolidated financial statements for the three and six months ended April 30, 2026. The company experienced a significant increase in net loss for both periods, with the six-month loss reaching $5,902,236 compared to $1,855,549 in the prior year. Despite the widening loss, total assets more than doubled to $14,523,512, and shareholders' equity saw a substantial rise to $11,490,741, largely due to financing activities including share issuances and convertible loan conversions. Operating expenses also increased significantly.
Key Highlights
- Clearmind Medicine Inc. reported a net loss of $2,047,653 for the three months ended April 30, 2026, compared to a net loss of $783,928 for the same period in 2025.
- For the six months ended April 30, 2026, the net loss was $5,902,236, a significant increase from $1,855,549 in the prior year period.
- Total assets grew to $14,523,512 as of April 30, 2026, from $6,083,052 as of October 31, 2025, primarily driven by an increase in cash and cash equivalents.
- Total liabilities decreased to $3,032,771 as of April 30, 2026, from $4,890,456 as of October 31, 2025.
- Shareholders' equity increased substantially to $11,490,741 as of April 30, 2026, from $1,192,596 as of October 31, 2025, due to share issuances and conversions.
- Operating expenses for the six months ended April 30, 2026, were $5,231,124, up from $2,803,155 in the comparable period of 2025.
- The company completed two reverse stock splits in the period: a 1-for-40 split on December 15, 2025, and a 1-for-10 split on May 21, 2026.
Price Impact
More from CMND